Market Overview

Expert: Bluebird Bio Is 'One Of The Better Stories In Biotech'

Expert: Bluebird Bio Is 'One Of The Better Stories In Biotech'
Related BLUE
ICYMI: T-Mobile Terrorizes Telecom Space, 2017 ASH Recap, Bitcoin Continues To Dominate The News Cycle
30 Biggest Movers From Yesterday
Market Volatility Bulletin: 'And We're Back!' (Seeking Alpha)

Adam Feuerstein was recently a guest on #PreMarket Prep, a daily trading idea radio show hosted by Joel Elconin and Dennis Dick.

TheStreet Senior Columnist Adam Feuerstein discussed bluebird bio Inc (NASDAQ: BLUE) on the show and said that it was “one of the better stories in biotech over the last year.”

Feuerstein said that bluebird was at the forefront of a group of companies that are working on gene therapy for diseases as the science and technology evolved from early stages.

Gene therapy, unlike traditional drugs, can potentially cure disease rather than just treat symptoms, according to Feuerstein.

Data was expected from the company this year on its sickle cell therapy which would follow December’s strong results from its beta thalassemia therapy, which Feuerstein said was exciting to investors.

Bluebird bio recently traded at $133.29, down 0.48 percent

Check out the full interview below. Feuerstein comes in at about the one-hour mark:

Posted-In: Adam Feuerstein TheStreetBiotech Exclusives Trading Ideas Interview General Best of Benzinga


Related Articles (BLUE)

View Comments and Join the Discussion!